To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Commons Chamber
NHS Long-Term Plan: Implementation - Mon 01 Jul 2019
Department of Health and Social Care

Mentions:
1: Jonathan Ashworth (LAB - Leicester South) expectancy have begun to stall, and even go backwards in the poorest areas. - Speech Link
2: Matt Hancock (IND - West Suffolk) life expectancy still further. - Speech Link
3: Janet Daby (LAB - Lewisham East) I have recently become the vice-chair of the all-party parliamentary group on sickle cell and thalassaemia - Speech Link
4: Matt Hancock (IND - West Suffolk) cell, and it was horrific to see the degree of pain that they were in. - Speech Link

Departmental Publication (Research and Statistics)
Department of Health and Social Care

Jul. 22 2019

Source Page: Chief Medical Officer annual report 2019: partnering for progress
Document: Chief Medical Officer annual report 2019: partnering for progress (PDF)

Found: On a global scale, development has made great strides, contributing to an increase in life expectancy

Non-Departmental Publication (Guidance and Regulation)
UK Visas and Immigration

Jun. 27 2019

Source Page: Ghana: country policy and information notes
Document: Ghana: country policy and information notes (PDF)

Found: Sickle cell anaemia ................................ ................................ .............

Written Question
Sickle Cell Diseases: Life Expectancy
Wednesday 5th June 2019

Asked by: Diana Johnson (Labour - Kingston upon Hull North)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of trends in the life expectancy of patients with sickle cell disease since 2000; and what steps he is taking to increase life expectancy for people suffering from that disease.

Answered by Seema Kennedy

Evidence suggests that life expectancy for people with sickle cell disease is improving. This is due to a number of factors including;

- Improved new born screening coverage to enable earlier diagnosis;

- Use of the National Haemoglobinopathy Registry to monitor individuals’ health, treatment and their annual reviews;

- Access to specific diagnostics and medication, such as hydroxyurea; and

- A Commissioning for Quality and Innovation incentive has been in place for the last two years to improve access to apheresis for individuals with sickle cell disease.

These factors are reflected in NHS England’s service specification quality indicators which providers are required to report against so that implementation can be monitored.

Deposited Papers
Ministry of Defence

Jun. 06 2019

Source Page: Joint Service Manual of Medical Fitness (JSMMF). JSP 950 Medical policy leaflet 6-7-7. Incl. annexes. 187p.
Document: Joint_Service_Manual_of_Medical_Fitness.pdf (PDF)

Found: Sickle cell t rait (Hb A/S).

Non-Departmental Publication (Statistics)
Public Health England (PHE)

Feb. 05 2019

Source Page: Public health outcomes framework: February 2019 data update
Document: Public health outcomes framework: February 2019 data update (PDF)

Found: series × Gender ONS 0.1ii Life expectancy at birth 2015 - 17 Updated

Select Committee
Evidence given by A patient representative nominated by the Cystic Fibrosis Trust, a clinician representative nominated by the Cystic Fibrosis TrustProfessor Stephen Powis, National Medical Director, John Stewart, National Director, Specialised Commissioning, NHS England, Sir Andrew Dillon, Chief Executive, Meindert Boysen, Director of the Centre for Health Technology Evaluation, NICEDr Jeff Leiden, Chairman, President and Chief Executive Officer, Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals
 07 Mar 2019 - Availability of Orkambi on the NHS - oral evidence

Oral Evidence Mar. 11 2019

Inquiry: Availability of Orkambi on the NHS
Inquiry Status: Closed
Committee: Health and Social Care Committee (Department: Department of Health and Social Care)

Found: expectancy and a minimal treatment burden.

Select Committee
A patient representative nominated by the Cystic Fibrosis Trust, a clinician representative nominated by the Cystic Fibrosis TrustProfessor Stephen Powis, National Medical Director, John Stewart, National Director, Specialised Commissioning, NHS England, Sir Andrew Dillon, Chief Executive, Meindert Boysen, Director of the Centre for Health Technology Evaluation, NICEDr Jeff Leiden, Chairman, President and Chief Executive Officer, Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals

Oral Evidence Mar. 07 2019

Inquiry: Availability of Orkambi on the NHS inquiry
Inquiry Status: Closed
Committee: Health and Social Care Committee (Department: Department of Health and Social Care)

Found: expectancy and a minimal treatment burden.

Departmental Publication (Closed consultation)
Department of Health and Social Care

Feb. 12 2019

Source Page: Public Health Outcomes Framework: proposed changes 2019 to 2020
Document: Public Health Outcomes Framework: proposed changes 2019 to 2020 (PDF)

Found: expectancy - at birth and at 65 0.1ii Life e xpectancy - at birth and at 65 0.2iii

Non-Departmental Publication (Closed consultation)
Public Health England (PHE)

Apr. 19 2018

Source Page: Guidelines for newborn blood spot sampling 2015
Document: Guidelines for newborn blood spot sampling 2015 (PDF)

Found: ) CF poor weight gain, frequent chest infections and reduced life expectancy (symptoms can